REGULATORY

MRSA Infections Add 190 Billion Yen Annually to Medical Expenditure at DPC Hospitals: MHLW Study Group

July 25, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Methicillin-resistant Staphylococcus aureus (MRSA) infections at all DPC hospitals add around 190 billion yen to the medical expenditure, around four million days of hospitalization, and some 14,000 deaths annually, according to an estimate by a study group of the Ministry…

To read the full story

G7 Leaders Vow to Consider New Incentives to Spur AMR R&D
May 30, 2016
Govt OKs Action Plan on Drug Resistance
April 6, 2016

REGULATORY

Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…